Immunity to citrullinated proteins in rheumatoid arthritis

Annual Review of Immunology

Volumn 26, Issue , 2008, Pages 651-675

  Klareskog, Lars ^a   Rönnelid, Johan ^a,b   Lundberg, Karin ^c   Padyukov, Leonid ^a   Alfredsson, Lars ^d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Autoimmunity; Environment; Genes; HLA DR; Smoking

Indexed keywords

ANTIBODY; ANTIGEN; ARGININE; ARGININE DEIMINASE; AUTOANTIBODY; BIOLOGICAL MARKER; CITRULLINE; CITRULLINE ANTIBODY; COLLAGEN TYPE 2; DISEASE MODIFYING ANTIRHEUMATIC DRUG; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN ARGININE DEIMINASE;

ADAPTIVE IMMUNITY; ARTHRITIS; CHEMICAL REACTION; CHEMICAL STRUCTURE; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE COURSE; GENE EXPRESSION; GENE FREQUENCY; GENE INTERACTION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; MEDICAL RESEARCH; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; RHEUMATOID ARTHRITIS; SMOKING;

ANIMALS; ARTHRITIS, RHEUMATOID; CITRULLINE; HLA-DR ANTIGENS; HUMANS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEINS;

EID: 42649092503     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.26.021607.090244     Document Type: Review

References (137)

1. Arnett FC, Edworthy SM, Block DA, McShane DJ, Fries JF, et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:315-24
2. Waaler E. 1940. On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. Acta Pathol. Microbiol. Scand. 17:172
3. Nemazee D. 1985. Immune complexes can trigger specific T-cell dependent autoanti-IgG antibody production in mice. J. Exp. Med. 161:242
4. Tarkowski A, Czerkinsky C, Nilsson LA. 1985. Simultaneous induction of rheumatoid factor- and antigen-specific antibody-secreting cells during the secondary immune response in man. Clin. Exp. Immunol. 61:379-87
5. Stastny P. 1978. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N. Engl. J. Med. 298:869-71
6. Gregersen PK, Silver J, Winchester RJ. 1987. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 30:1205-13
7. Klareskog L, Forsum U, Scheynius A, Kabelitz D, Wigzell H. 1982. Evidence in support of a self-perpetuating HLA-DR-dependent delayed-type cell reaction in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 79:3632-36
8. + T cells in synovial fluid and tissues of patients with rheumatoid arthritis. Arthritis Rheum. 24:1370-76
9. Edwards JC, Cambridge G. 2001. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 40:205-11
10. Skapenko A, Lipsky PE, Schulze-Koops H. 2006. T cell activation as starter and motor of rheumatic inflammation. Curr. Top. Microbiol. Immunol. 305:195-211
11. Feldmann M, Brennan FM, Williams RO, Woody JN, Maini RN. 2004. The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 18:59-80
12. McInnes IB, Liew FY. 2005. Cytokine networks - toward new therapies for rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 1:31-39
13. Firestein GS. 2005. Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J. Clin. Rheumatol. 11:S39-44
14. Tak PP. 2006. Chemokine inhibition in inflammatory arthritis. Best Pract. Res. Clin. Rheumatol. 20:929-39
15. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, et al. 2000. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 43:155-63
16. Vincent C, Nogueira L, Sebbag M, Chapuy-Regaud S, Arnaud M, et al. 2002. Detection of antibodies to deiminated recombinant rat filaggrin by enzyme-linked immunosorbent assay: a highly effective test for the diagnosis of rheumatoid arthritis. Arthritis Rheum. 46:2051-58
17. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, et al. 2004. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum. 50:709-15
18. Avouac J, Gossec L, Dougados M. 2006. Diagnostic and predictive value of anticyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann. Rheum. Dis. 65:845-51
19. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, et al. 2007. Meta-analysis: diagnostic accuracy of anticyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann. Intern. Med. 146:797-808
20. Kurki P, Aho K, Palosuo T, Heliovaara M. 1992. Immunopathology of rheumatoid arthritis. Antikeratin antibodies precede the clinical disease. Arthritis Rheum. 35:914-17
21. Aho K, Palosuo T, Heliovaara M, Knekt P, Alha P, von Essen R. 2000. Antifilaggrin antibodies within "normal" range predict rheumatoid arthritis in a linear fashion. J. Rheumatol. 27:2743-46
22. Rantapää-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, et al. 2003. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 48:2741-49
23. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, et al. 2004. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 50:380-86
24. Kastbom A, Strandberg G, Lindroos A, Skogh T. 2004. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann. Rheum. Dis. 63:1085-89
25. Rönnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, et al. 2005. Longitudinal analysis of anticitrullinated protein/peptide antibodies (anti-CP) during 5 year follow-up in early rheumatoid arthritis: anti-CP status is a stable phenotype that predicts worse disease activity and greater radiological progression. Ann. Rheum. Dis. 64:1744-49
26. Klareskog L, Stolt P, Lundberg K, Källberg H, Bengtsson C, et al. 2006. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 54:38-46
27. van der Helm-van Mil AH, Verpoort KN, le Cessie S, Huizinga TW, de Vries RR, Toes RE. 2007. The HLA-DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. Arthritis Rheum. 56:425-32
28. Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, et al. 2006. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J. Clin. Invest. 116:961-73
29. Lundberg K, Nijenhuis S, Vossenaar ER, Palmblad K, van Venrooij WJ, et al. 2005. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res. Ther. 7:R458-67
30. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ. 2003. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. BioEssays 25:1106-18
31. Chavanas S, Mechin MC, Takahara H, Kawada A, Nachat R, et al. 2004. Comparative analysis of the mouse and human peptidylarginine deiminase gene clusters reveals highly conserved noncoding segments and a new human gene, PADI6. Gene 330:19-27
32. Baeten D, Peene I, Union A, Meheus L, Sebbag M, et al. 2001. Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis Rheum. 44:2255-62
33. Gyorgy B, Toth E, Tarcsa E, Falus A, Buzas EI. 2006. Citrullination: a posttranslational modification in health and disease. Int. J. Biochem. Cell Biol. 38:1662-17
34. Kubilus J, Waitkus RW, Baden HP. 1979. The presence of citrullinein epidermal proteins. Biochim. Biophys. Acta 581:114-21
35. Nicholas AP, King JL, Sambandam T, Echols JD, Gupta KB, et al. 2003. Immunohistochemical localization of citrullinated proteins in adult rat brain. J. Comp. Neurol. 459:251-66
36. Moscarello MA, Mastronardi FG, Wood DD. 2007. The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis. Neurochem. Res. 32:251-56
37. Ireland J, Herzog J, Unanue ER. 2006. Cutting edge: unique T cells that recognize citrullinated peptides are a feature of protein immunization. J. Immunol. 177:1421-25
38. Vossenaar ER, Smeets TJ, Kraan MC, Raats JM, van Venrooij WJ, Tak PP. 2004. The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum. 50:3485-94
39. Bongartz T, Cantaert T, Atkins SR, Harle P, Myers JL, et al. 2007. Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology 46:70-75
40. Nicholas AP, Whitaker JN. 2002. Preparation of a monoclonal antibody to citrullinated epitopes: its characterization and some applications to immunohistochemistry in human brain. Glia 37:328-36
41. Makrygiannakis D, af Klint E, Lundberg IE, Löfberg R, Ulfgren AK, et al. 2006. Citrullination is an inflammation-dependent process. Ann. Rheum. Dis. 65:1219-22
42. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, et al. 2001. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the α- and β-chains of fibrin. J. Immunol. 166:4177-84
43. Vossenaar ER, Despres N, Lapointe E, van der Heijden A, Lora M, et al. 2004. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res. Ther. 6:R142-50
44. Bang H, Egerer K, Gauliard A, Lüthke K, Rudulph PE, et al. 2007. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum. 56:2503-11
45. Young BJ, Mallya RK, Leslie RD, Clark CJ, Hamblin TJ. 1979. Anti-keratin antibodies in rheumatoid arthritis. Br. Med. J. 2:97-99
46. Nienhuis RL, Mandena E. 1964. A new serum factor in patients with rheumatoid arthritis, the antiperiuclear factor. Ann. Rheum. Dis. 23:202-5
47. Simon M, Girbal E, Sebbag M, Gomes-Daudrix V, Vincent C, et al. 1993. The cytokeratin filament-aggregating protein filaggrin is the target of the so-called "antikeratin antibodies," autoantibodies specific for rheumatoid arthritis. J. Clin. Invest. 92:1387-93
48. Sebbag M, Simon M, Vincent C, Masson-Bessiere C, Girbal E, et al. 1995. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J. Clin. Invest. 95:2672-79
49. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. 1998. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J. Clin. Invest. 101:273-81
50. Nijenhuis S, Zendman AJ, Vossenaar ER, Pruijn GJ, van Venrooij WJ. 2004. Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clin. Chim. Acta. 350:17-34
51. Girbal-Neuhauser E, Durieux JJ, Arnaud M, Dalbon P, Sebbag M, et al. 1999. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J. Immunol. 162:585-94
52. Vander Cruyssen B, Cantaert T, Nogueira L, Clavel C, De Rycke L, et al. 2006. Diagnostic value of antihuman citrullinated fibrinogen ELISA and comparison with four other anticitrullinated protein assays. Arthritis Res. Ther. 8:R122
53. Despres N, Boire G, Lopez-Longo FJ, Menard HA. 1994. The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis. J. Rheumatol. 21:1027-33
54. Hayem G, Chazerain P, Combe B, Elias A, Haim T, et al. 1999. Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. J. Rheumatol. 26:7-13
55. Hueber W, Hassfeld W, Smolen JS, Steiner G. 1999. Sensitivity and specificity of anti-Sa autoantibodies for rheumatoid arthritis. Rheumatology 38:155-59
56. Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M. 2006. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res. Ther. 8:R119
57. Kinloch A, Tatzer V, Wait R, Peston D, Lundberg K, et al. 2005. Identification of citrullinated α-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res. Ther. 7:R1421-29
58. Trentham DE, Townes AS, Kang AH. 1977. Autoimmunity to type II collagen an experimental model of arthritis. J. Exp. Med. 146:857-68
59. Holmdahl R, Bockermann R, Backlund J, Yamada H. 2002. The molecular pathogenesis of collagen-induced arthritis in mice - a model for rheumatoid arthritis. Ageing Res. Rev. 1:135-47
60. Terato KJ, Shimozuru Y, Katyama K, Takemitzu Y, Yamashita I, et al. 1990. Specificity of antibodies to type II collagen in rheumatoid arthritis. Arthritis Rheum. 33:1493-500
61. Tarkowski A, Klareskog L, Carlsten H, Herberts P, Koopman WJ. 1989. Secretion of antibodies to types I and II collagen by synovial tissue cells in patients with rheumatoid arthritis. Arthritis Rheum. 32:1087-92
62. Rönnelid J, Lysholm J, Engström-Laurent A, Klareskog L, Heyman B. 1994. Local anti-type II collagen antibody production in rheumatoid arthritis synovial fluid. Evidence for an HLA-DR4-restricted IgG response. Arthritis Rheum. 37:1023-29
63. Burkhardt H, Sehnert B, Bockermann R, Engstrom A, Kalden JR, Holmdahl R. 2005. Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur. J. Immunol. 35:1643-52
64. Verpoort KN, Jol-van der Zijde CM, Papendrecht-van der Voort EA, Ioan-Facsinay A, Drijfhout JW, et al. 2006. Isotype distribution of anticyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum. 54:3799-808
65. Caramaschi P, Biasi D, Tonolli E, Pieropan S, Martinelli N, et al. 2005. Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatol. Int. 26:58-62
66. De Rycke L, Verhelst X, Kruithof E, Van den Bosch F, Hoffman IE, et al. 2005. Rheumatoid factor, but not anticyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann. Rheum. Dis. 64:299-302
67. Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C. 2004. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res. Ther. 6:R264-72
68. Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, et al. 2004. Decrease of anticyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFα therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann. Rheum. Dis. 63:1218-21
69. Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, et al. 2006. The effect of etanercept on anticyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann. Rheum. Dis. 65:35-39
70. Bogliolo L, Alpini C, Caporali R, Scire CA, Moratti R, Montecucco C. 2005. Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J. Rheumatol. 32:511-15
71. Korendowych E, Owen P, Ravindran J, Carmichael C, McHugh N. 2005. The clinical and genetic associations of anticyclic citrullinated peptide antibodies in psoriatic arthritis. Rheumatology 44:1056-60
72. Vander Cruyssen B, Hoffman IE, Zmierczak H, Van den Berghe M, Kruithof E, et al. 2005. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann. Rheum. Dis. 64:1145-49
73. Alenius GM, Berglin E, Rantapaa Dahlqvist S. 2006. Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation. Ann. Rheum. Dis. 65:398-400
74. Low JM, Chauhan AK, Kietz DA, Daud U, Pepmueller PH, Moore TL. 2004. Determination of anticyclic citrullinated peptide antibodies in the sera of patients with juvenile idiopathic arthritis. J. Rheumatol. 31:1829-33
75. Kasapcopur O, Altun S, Aslan M, Karaarslan S, Kamburoglu-Goksel A, et al. 2004. Diagnostic accuracy of anticyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann. Rheum. Dis. 63:1687-89
76. Ferucci ED, Majka DS, Parrish LA, Moroldo MB, Ryan M, et al. 2005. Antibodies against cyclic citrullinated peptide are associated with HLA-DR4 in simplex and multiplex polyarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 52:239-46
77. Kwok JS, Hui KH, Lee TL, Wong W, Lau YL, et al. 2005. Anti-cyclic citrullinated peptide: diagnostic and prognostic values in juvenile idiopathic arthritis and rheumatoid arthritis in a Chinese population. Scand. J. Rheumatol. 34:359-66
78. Martinez JB, Valero JS, Bautista AJ, Restrepo JF, Matteson EL, et al. 2007. Erosive arthropathy: clinical variance in lupus erythematosus and association with anti-CCP case series and review of the literature. Clin. Exp. Rheumatol. 25:47-53
79. Takasaki Y, Yamanaka K, Takasaki C, Matsushita M, Yamada H, et al. 2004. Anticyclic citrullinated peptide antibodies in patients with mixed connective tissue disease. Mod. Rheumatol. 14:367-75
80. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, et al. 2000. The prognostic value of anticyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 43:1831-35
81. Forslind K, Ahlmen M, Eberhardt K, Hafström I, Svensson B. 2004. Prediction of radiological outcome in early RA in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann. Rheum. Dis. 63:1090-95
82. Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, et al. 2003. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann. Rheum. Dis. 62:427-30
83. Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, et al. 2003. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann. Rheum. Dis. 62:120-26
84. van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, et al. 2007. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 56:1424-32
85. Wordsworth BP, Lanchbury JSS, Sakkas LI, Welsh KI, Panayi GS, Bell JI. 1989. HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. Proc. Natl. Acad. Sci. USA 86:10049-53
86. Khan MA, Mathieu A, Sorrentino R, Akkoc N. 2007. The pathogenetic role of HLA-B27 and its subtypes. Autoimmun. Rev. 6:183-89
87. Huizinga TW, Amos CI, van der Helm-van Mil AH, Chen W, van Gaalen FA, et al. 2005. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum. 52:3433-38
88. van der Helm-van Mil AR, Verpoort KN, Breedveld FC, Huizinga TW, Toes RE, de Vries RR. 2006. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anticyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum. 54:1117-21
89. Irigoyen P, Lee AT, Wener MH, Li W, Kern M, et al. 2005. Regulation of anticyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles. Arthritis Rheum. 52:3813-18
90. Plenge RM, Padyukov L, Remmers EF, Purcell S, Lee AT, et al. 2005. Replication of putative candidate-gene associations with rheumatoid arthritis in >4000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am. J. Hum. Genet. 77:1044-60
91. Wesoly J, van der Helm-van Mil AH, Toes RE, Chokkalingam AP, Carlton VE, et al. 2005. Association of the PTPN22 C1858T single-nucleotide polymorphism with rheumatoid arthritis phenotypes in an inception cohort. Arthritis Rheum. 52:2948-50
92. Källberg H, Padyukov L, Plenge RM, Rönnelid J, Gregersen PK, et al. 2007. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am. J. Hum. Genet. 80:867-75
93. Sigurdsson S, Padyukov L, Kurreeman FA, Liljedahl U, Wiman AC, et al. 2007. Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. Arthritis Rheum. 56:2202-10
94. Lorentzen JC, Flomes L, Eklöw C, Bäckdahl L, Ribbhammar U, et al. 2007. Association with arthritis of a gene complex encoding C-type lectin-like receptors. Arthritis Rheum. 56:2620-32
95. Aho K, Heliovaara M, Maatela J, Tuomi T, Palosuo T. 1991. Rheumatoid factors antedating clinical rheumatoid arthritis. J. Rheumatol. 18:1282-84
96. Duplan V, Foulquier C, Clavel C, Al Badine R, Serre G, et al. 2006. In the rat, citrullinated autologous fibrinogen is immunogenic but the induced autoimmune response is not arthritogenic. Clin. Exp. Immunol. 145:502-12
97. Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, et al. 2004. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am. J. Hum. Genet. 75:330-37
98. Gregersen PK. 2005. Pathways to gene identification in rheumatoid arthritis: PTPN22 and beyond. Immunol. Rev. 204:74-86
99. Johansson M, Arlestig L, Hallmans G, Rantapaa-Dahlqvist S. 2006. PTPN22 polymorphism and anticyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease. Arthritis Res. Ther. 8:R19
100. Kokkonen H, Johansson M, Innala L, Eriksson C, Jidell E, Rantapaa Dahlqvist S. 2007. The PTPN22 1858C/T polymorphism is associated with anticyclic citrullinated peptide antibody positive early rheumatoid arthritis in northern Sweden. Arthritis Res. Ther. 9:R56
101. Pierer M, Kaltenhauser S, Arnold S, Wahle M, Baerwald C, et al. 2006. Association of PTPN22 1858 single-nucleotide polymorphism with rheumatoid arthritis in a German cohort: higher frequency of the risk allele in male compared to female patients. Arthritis Res. Ther. 8:R75
102. Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, et al. 2007. Genome-wide search identifies TRAF1-C5 as rheumatoid arthritis risk locus. N. Engl. J. Med. 357:1199-209
103. Seielstad M, Padyukov L, Ding B, Plenge RM, Alfredsson L, Klareskog L. 2007. A genome-wide SNP association study identifies novel risk loci for rheumatoid arthritis in Swedish EIRA study. Ann. Rheum. Dis. 66(Suppl. II):680
104. Heliovaara M, Aho K, Aromaa A, Knekt P, Reunanen A. 1993. Smoking and risk of rheumatoid arthritis. J. Rheumatol. 20:1830-35
105. Silman AJ, Newman J, MacGregor AJ. 1996. Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins. Arthritis Rheum. 39:732-35
106. Uhlig T, Hagen KB, Kvien TK. 1999. Current tobacco smoking, formal education, and the risk of rheumatoid arthritis. J. Rheumatol. 26:47-54
107. Stolt P, Bengtsson C, Nordmark B, Lindblad S, Lundberg I, et al. 2003. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann. Rheum. Dis. 62:835-41
108. Masdottir B, Jonsson T, Manfredsdottir V, Vikingsson A, Brekkan A, Valdimarsson H. 2000. Smoking, rheumatoid factor isotypes and severity of rheumatoid arthritis. Rheumatology 39:1202-5
109. Wolfe F. 2000. The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. J. Rheumatol. 27:630-37
110. Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L. 2004. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum. 50:3085-92
111. Pedersen M, Jacobsen S, Garred P, Madsen HO, Klarlund M, et al. 2007. Strong combined gene-environment effects in anticyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in Denmark. Arthritis Rheum. 56:1446-53
112. Källberg H, Padyukov L, Bengtsson C, Rönnelid J, Klareskog L, Alfredsson L. 2007. Smoking is associated with anti-CCP positive RA in a dose dependent manner, results from the Swedish EIRA study. Ann. Rheum. Dis. 66(Suppl. II):291
113. Lee HS, Irigoyen P, Kern M, Lee A, Batliwalla F, et al. 2007. Interaction between smoking, the shared epitope, and anticyclic citrullinated peptide: a mixed picture in three large North American rheumatoid arthritis cohorts. Arthritis Rheum. 56:1745-53
114. Sverdrup B, Kallberg H, Bengtsson C, Lundberg I, Padyukov L, et al. 2005. Association between occupational exposure to mineral oil and rheumatoid arthritis: results from the Swedish EIRA case-control study. Arthritis Res. Ther. 7:R1296-303
115. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E. 2003. The conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J. Immunol. 171:538-41
116. Tsuji Y, Akiyama M, Arita K, Senshu T, Shimizu H. 2003. Changing pattern of deiminated proteins in developing human epidermis. J. Invest. Dermatol. 120:817-22
117. Casciola-Rosen LA, Anhalt G, Rosen A. 1994. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J. Exp. Med. 179:1317-30
118. Suzuki A, Yamada R, Chang X, Tokuhiro S, Sawada T, et al. 2003. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat. Genet. 34:395-402
119. Kang CP, Lee HS, Ju H, Cho H, Kang C, Bae SC. 2006. A functional haplotype of the PADI4 gene associated with increased rheumatoid arthritis susceptibility in Koreans. Arthritis Rheum. 54:90-96
120. Barton A, Bowes J, Eyre S, Spreckley K, Hinks A, et al. 2004. A functional haplotype of the PADI4 gene associated with rheumatoid arthritis in a Japanese population is not associated in a United Kingdom population. Arthritis Rheum. 50:1117-21
121. Caponi L, Petit-Teixeira E, Sebbag M, Bongiorni F, Moscato S, et al. 2005. A family based study shows no association between rheumatoid arthritis and the PADI4 gene in a white French population. Ann. Rheum. Dis. 64:587-93
122. Harney SM, Meisel C, Sims AM, Woon PY, Wordsworth BP, Brown MA. 2005. Genetic and genomic studies of PADI4 in rheumatoid arthritis. Rheumatology 44:869-72
123. Martinez A, Valdivia A, Pascual-Salcedo D, Lamas JR, Fernandez-Arquero M, et al. 2005. PADI4 polymorphisms are not associated with rheumatoid arthritis in the Spanish population. Rheumatology 44:1263-66
124. Nissinen R, Paimela L, Julkunen H, Tienari PJ, Leirisalo-Repo M, et al. 2003. Peptidyl-arginine deiminase, the arginine to citrulline converting enzyme, is frequently recognized by sera of patients with rheumatoid arthritis, systemic lupus erythematosus and primary Sjogren syndrome. Scand. J. Rheumatol. 32:337-42
125. Roth EB, Stenberg P, Book C, Sjoberg K. 2006. Antibodies against transglutaminases, peptidylarginine deiminase and citrulline in rheumatoid arthritis - new pathways to epitope spreading. Clin. Exp. Rheumatol. 24:12-18
126. Caplan A. 1963. Contribution to discussion on rheumatoid pneumoconiosis. Grundfr. Silikoseforsch. 6:345-49
127. Pratesi F, Tommasi C, Anzilotti C, Chimenti D, Migliorini P. 2006. Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anticitrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum. 54:733-41
128. Katz J, Goultschin J, Benoliel R, Brautbar C. 1987. Human leukocyte antigen (HLA) DR4. Positive association with rapidly progressing periodontitis. J. Periodontol. 58:607-10
129. Marotte H, Farge P, Gaudin P, Alexandre C, Mougin B, Miossec P. 2006. The association between periodontal disease and joint destruction in rheumatoid arthritis extends the link between the HLA-DR shared epitope and severity of bone destruction. Ann. Rheum. Dis. 65:905-9
130. Heinlen LD, McClain MT, Merrill J, Akbarali YW, Edgerton CC, et al. 2007. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum. 56:2344-51
131. Jansen AL, van der Horst-Bruinsma I, van Schaardenburg D, van de Stadt RJ, de Koning MH, Dijkmans BA. 2002. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J. Rheumatol. 29:2074-76
132. Matsumoto I, Staub A, Benoist C, Mathis D. 1999. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 286:1732-35
133. Binstadt BA, Patel PR, Alencar H, Nigrovic PA, Lee DM, et al. 2006. Particularities of the vasculature can promote the organ specificity of autoimmune attack. Nat. Immunol. 7:284-92
134. Hulsemann JL, Zeidler H. 1995. Undifferentiated arthritis in an early synovitis outpatient clinic. Clin. Exp. Rheumatol. 13:37-43
135. Nielen MM, van der Horst AJR, van Schaardenburg D, van der Horst-Bruinsma IE, van de Stadt RJ, et al. 2005. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann. Rheum. Dis. 64:1199-204
136. Wellcome Trust Case Control Consort. 2007. Genome-wide association study of 14,000 cases of seven common diseases and 3000 shared controls. Nature 447:661-78
137. Hueber W, Kidd BA, Tomooka BH, Lee BJ, Bruce B, et al. 2005. Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum. 52:2645-55